 |
Previous Article | Next Article 
Volume 17, Number 11,
Issue of June 1, 1997
pp. 4112-4120
Copyright ©1997 Society for Neuroscience
Bone Morphogenetic Proteins Induce Astroglial Differentiation of
Oligodendroglial-Astroglial Progenitor Cells
P. C. Mabie,
M. F. Mehler,
R. Marmur,
A. Papavasiliou,
Q. Song, and
J. A. Kessler
Departments of Neurology and Neuroscience and the R. F. Kennedy
Center for Research in Mental Retardation and Human Development, Albert
Einstein College of Medicine, Bronx, New York 10461
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
FOOTNOTES
REFERENCES
ABSTRACT
We have used bipotent postnatal cortical
oligodendroglial-astroglial progenitor cells (O-2As) to examine the
role of inductive signals in astroglial lineage commitment. O-2A
progenitor cells undergo progressive oligodendroglial differentiation
when cultured in serum-free medium, but differentiate into astrocytes
in medium supplemented with FBS. We now report that the bone
morphogenetic proteins (BMPs), a major subclass of the transforming
growth factor (TGF ) superfamily, promote the selective,
dose-dependent differentiation of O-2As into astrocytes with concurrent
suppression of oligodendroglial differentiation. This
astroglial-inductive action is not sanctioned by other members of the
TGF superfamily. Astroglial differentiation requires only very brief
initial exposure to the BMPs and is accompanied by increased cellular
survival and accelerated exit from cell cycle. Dual-label
immunofluorescence microscopy documents that O-2A progenitor cells
express a complement of BMP type I and type II receptor subunits
required for signal transduction. Furthermore, expression of BMP2
in vivo reaches maximal levels during the period of
gliogenesis. These results suggest that the BMPs act as potent inductive factors in postnatal glial lineage commitment that initiate a
stable program of astroglial differentiation.
Key words:
astrocyte;
bone morphogenetic protein;
lineage
commitment;
oligodendrocyte-astrocyte type 2 progenitor;
transforming
growth factor superfamily;
central nervous system development
INTRODUCTION
Normal mammalian CNS development requires the
progressive elaboration of diverse, highly specialized cell types that
populate the mature brain. The mechanisms underlying this developmental process are not well understood. Studies of the Drosophila
nervous system and the mammalian PNS suggest that diversification
occurs through progressive lineage restriction of early multipotent
progenitors into bipotent and ultimately unipotent precursor cells (for
review, see Jan and Jan, 1995 ) (Anderson, 1989 ). According to this
schema, extracellular signals may play an essential role in
development, both as inductive agents at points of lineage restriction
and as selective mitogenic or survival factors for stable progenitor or
mature cellular populations.
Oligodendrocyte-type 2 astrocyte progenitor cells (O-2As) have
been studied in vitro to examine the effects of
extracellular signaling on lineage commitment, survival, and
proliferation of bipotent neural cells (Raff et al., 1983 ). Initially
cultured from rat optic nerve and later from rat cerebrum (McCarthy and DeVellis, 1980 ), O-2As are well suited to the study of differentiation, because their development into oligodendrocytes or astrocytes depends
on differential environment signals (Temple and Raff, 1985 ). O-2As are
characterized by A2B5 and GD3 immunoreactivity in vitro
(Raff et al., 1983 ; Levison and Goldman, 1993 ). O-2As cultured in
serum-free defined medium proceed through several well-characterized
morphological and antigenic developmental stages as they differentiate
into mature oligodendroglia, whereas O-2As cultured in FBS develop
almost exclusively into astroglia within 3 d (Raff et al., 1983 ).
These observations suggest that for O-2A progenitor cells, the
oligodendroglial fate is constitutive, and the astroglial fate requires
active induction. Clonal analysis of O-2As that were switched from
medium containing 1-10% FBS revealed the presence of mixed clones
containing both oligodendrocytes and astrocytes, demonstrating
plasticity of O-2A lineage development (Lubetzki et al., 1992 ). The
astrocyte-inductive factor(s) present in serum has not been identified.
Ciliary neurotrophic factor (CNTF) is known to transiently stimulate
O-2A glial fibrillary acidic protein (GFAP) expression without
ultimately influencing lineage fate (Hughes et al., 1988 ; Lillien and
Raff, 1990 ). However, CNTF combined with molecules present in the
extracellular matrix (ECM) of meningeal or endothelial cells does
stably induce the type 2 astrocyte phenotype (Lillien et al., 1990 ).
Interestingly, the ECM-associated molecules inhibit oligodendrocyte
differentiation in the absence of CNTF. More recently, leukemia
inhibitory factor (LIF) and oncostatin M, two other cytokines that
signal through the same gp130/LIF receptor (LIFR ) subunits as
CNTF, have been shown to have similar developmental effects (Gard et
al., 1995 ). The CNTF/ECM astrocyte-inductive activity is restricted to
early O-2As before developing O4 immunoreactivity, whereas the FBS
astrocyte-inductive activity continues through the O4-immunoreactive
stage of O-2A development (Gard et al., 1995 ). Several additional
cytokines have been identified that promote survival or proliferation
of O-2As at various developmental stages. Among these are
platelet-derived growth factor (PDGF), basic fibroblast growth factor
(bFGF), neurotrophin 3, and insulin-like growth factor (Barres and
Raff, 1994 ). Additional molecules that support oligodendroglial
differentiation include thyroid hormones, retinoic acid, and
hydrocortisone (Barres and Raff, 1994 ).
The study of glial progenitor lineage commitment in
vivo has been more difficult (for discussion, see Skoff and Knapp,
1991 ; Cameron and Rakic, 1991 ; Levison and Goldman, 1993 ). Many studies of mammalian embryonic and postnatal progenitors have suggested that
proliferative cells of the ventricular zone (VZ) and subventricular zone (SVZ) give rise to progeny predominantly restricted to one lineage
(Luskin et al., 1988 ; Price and Thurlow, 1988 ). More recently, a study
using retroviral labeling of postnatal SVZ cells has found that up to
15% of labeled clones contained both oligodendroglial and astroglial
cell types, compelling in vivo evidence for a bipotent oligodendroglial-astroglial progenitor cell (Levison and Goldman, 1993 ). This study also noted that the destination of SVZ progenitor migration correlated strongly with the phenotype of the progenitor's progeny, suggesting that environmental signals may play a role in
specifying cell fate. The identification of multipotent progenitors from the adult SVZ (Reynolds and Weiss, 1992 ; Lois and Alvarez-Buylla, 1993 ) and of O-2As from the adult optic nerve (Wolswijk and Noble, 1992 ) and cortex (Norton et al., 1988 ; Gard and Pfeiffer, 1989 ) suggests that the study of O-2A differentiation may have relevance to
models of CNS disease as well as development. Transplantation studies
have demonstrated O-2A lineage plasticity by following their fate
in vivo. When transplanted into glial-depleted regions of
the CNS, O-2As develop into both oligodendrocytes and astrocytes (for
review, see Franklin and Blakesmore, 1995). In demyelinating disease,
cells have been identified that label with both O-2A (O4) and astrocyte
(GFAP)-specific antibodies (Godfraind et al., 1989 ).
The bone morphogenetic protein (BMP) subclass of the TGF superfamily
has only recently gained attention in the study of mammalian CNS
development (for review of the TGF superfamily, see Kingsley, 1994 ;
for review of the BMPs, see Hogan, 1996 ). BMP4 has been implicated in
ventral mesoderm induction (Harland, 1994 ) and is now thought to
sanction epidermal and inhibit neural fate during Xenopus
gastrulation (Sasai et al., 1995 ; Wilson and Hemmati-Brivanlou, 1995 ).
In the chick neural tube, dorsal cell fates are induced by BMP4 and/or
BMP7 expressed in the overlying epidermal ectoderm (Liem et al., 1995 ).
Dorsal neural tube expression of BMP4 has been implicated in selective
apoptosis of hindbrain rhombomeres 3 and 5 (Graham et al., 1994 ). The
BMPs have been implicated in several aspects of neural crest progenitor
differentiation, including neuronal lineage commitment (Shah et al.,
1996 ) and the acquisition of the adrenergic phenotype (Reissmann et
al., 1996 ). In the rodent, BMP4 and BMP6 are expressed in early
embryonic brain (Jones et al., 1991 ; Schluesener and Meyermann, 1994 ).
Mice deficient in BMP2 and BMP4 show early embryonic lethality (Winnier
et al., 1995 ; Hogan, 1996 ), whereas mice deficient in BMP7 have
developmental abnormalities of the eyes and kidneys (Dudley et al.,
1995 ; Luo et al., 1995 ).
BMP ligands signal as homodimers or heterodimers that interact with at
least two receptor subunits, called type I and type II (Kingsley, 1994 ;
ten Dijke et al., 1994a ,b ). Studies with transfected COS cells suggest
that high-affinity binding may occur between the ligands BMP4 and BMP7
and a type I receptor alone but is enhanced by the presence of a type
II receptor (ten Dijke et al., 1994c ). In Drosophila, the
BMP homolog decapentaplegic requires the presence of both type I and
type II receptor subunits for active signal transduction (Letsou et
al., 1995 , Ruberte et al., 1995 ). There are currently three BMP type I
receptors identified and cloned, initially called activin receptor-like
kinases (ALKs) 2, 3, and 6, based on homology to the activin type I
receptor (ten Dijke et al., 1994a ,b ,c ). ALKs 3 and 6 bind BMPs but not
activin or any other known TGF factors (ten Dijke et al., 1994c );
thus, they have been called BMP type I receptors Ia and Ib. A type II receptor specific for the BMPs has also been cloned (BMPRII)
(Rosenzweig et al., 1995 ). Each of these receptors is expressed in the
developing mouse brain (ten Dijke et al., 1994b ,c ; Rosenzweig et al.,
1995 ). Mice deficient in BMPR Ia die before gastrulation (Mishina et al., 1995 ).
MATERIALS AND METHODS
O-2A cultures. Rat postnatal day 2 (P2) cortex was
dissected and dissociated mechanically by repeated trituration in
DMEM/F12 1:1 supplemented with 10% FBS, glucose (6 mg/ml), and
glutamine (2 mM), and then filtered through a 60 µm Nytex
filter. Cells were then pelleted, resuspended, and plated onto
poly-D-lysine (PDL, 20 µg/ml for 1 hr)-coated T75
flasks at 1.5 brains per flask. Cultures were fed twice per week, and
~2 d after reaching confluence (total of 9-10 d in
vitro), flasks were shaken for 3 hr at 250 rpm to remove
microglia, refed, and then shaken overnight at 300 rpm to remove O-2As.
Collected O-2As were further purified by passing through a 60 µm
Nytex filter and preplating on uncoated plastic dishes for 2 hr to
remove contaminating microglia. Cells were then pelleted, resuspended
in serum-free medium (SFM), counted, and plated at ~104
cells per well in PDL-coated 24-well plates. SFM consisted of DMEM/F12
(1:1) with glucose (6 ng/ml), glutamine (2 mM), BSA
(0.1 mg/ml), transferrin (50 µg/ml), triiodothyronine
(30 nM), hydrocortisone (20 nM), progesterone
(20 nM), biotin (10 nM), selenium (30 nM), and insulin (5 µg/ml). For 48 hr before
experimental manipulation, bFGF (2.5 ng/ml) and PDGF AA (2.5 ng/ml) were added. Some cells were grown on 9 mm glass
coverslips coated with PDL for dual-label immunofluorescent analysis.
Cells were maintained in a humidified incubator with 5% C02 at 37°C.
Control cultures were fed every 2 d, and BMP-treated cultures
received fresh medium and growth factors every 4 d. O-2A cultures
analyzed at the beginning of the experimental manipulation contained at
least 95% cells immunoreactive to the O-2A-associated antibodies GD3
and A2B5.
Immunocytochemistry. At the designated time, SFM was
withdrawn and cells were fixed with ice-cold absolute methanol for 10 min. For GD3, A2B5, O4, and galactocerebroside immunocytochemistry, cells were incubated with antibodies for 30 min at 4°C, followed by
washing and fixing. After treatments with 0.3%
H2O2 for 20 min and blocking serum (5% goat
serum) for 30 min, primary antibodies to intracellular antigens were
applied for 2 hr at room temperature. Appropriate biotinylated
secondary antibodies (Vector Laboratories, Burlingame, CA) were applied
at 1:200 dilution for 30 min, followed by application of the ABC
reagent (Vector) for 1 hr. The peroxidase reaction was performed with
visualization of label using diaminobenzidine 0.5 mg/ml as
substrate in 50 mM Tris, pH 7.6, containing 0.01% H2O2 for 5 min. All steps were followed by
washes in PBS, pH 7.4, except the blocking serum step. For analysis of
bromodeoxyuridine (BrdU) incorporation, cells were pulsed with 1 µM BrdU for 24 hr before fixation, and cells were treated
with 2N HCl for 30 min and sodium borate, pH 8, for 10 min before
application of blocking serum. For dual-label immunofluorescence, cells
grown on coverslips were incubated with primary antibodies as above and
then incubated with the appropriate fluoroscein and
rhodamine-conjugated secondary antibodies (Southern Biotechnology,
Alabaster, AL) at 1:100 dilution for 1 hr; coverslips were mounted onto
glass slides using a Molecular Probe (Eugene, OR) anti-fade mounting
kit following the manufacturer's protocol. Controls were performed
without primary antibody, with alternate primary antibodies, and with
inappropriate secondary antibodies, and showed negligible
background.
Western blot. Protein samples were prepared by manually
homogenizing the whole brains of P8 and adult mice in 50 mM
Tris-Cl, 0.15 M NaCl, pH 7.6, containing 10% glycerol,
0.1% NP-40, 0.1% Triton X-100, 0.1% SDS, 1 mM PMSF, and
0.3 mM sodium orthovanadate (lysis buffer). After
centrifugation, samples were quantitated by the Micro BCA Protein Assay
method (Pierce, Rockford, IL) following the manufacturer's protocol.
Samples were resolved by SDS-PAGE on 10% acrylamide gels (Bio-Rad
ready-made, Hercules, CA) using a Mini-PROTEAN II system (Bio-Rad) at
85 V, and then transferred by immersion at 300 mA overnight onto
nitrocellulose membranes. BMP2 was detected using a mouse monoclonal
antibody to BMP2 diluted 1:1500 in PBS containing 5% nonfat dried milk
(Blotto) for 4 hr at room temperature, followed by incubation with a
horseradish peroxidase-conjugated secondary antibody (Amersham,
Arlington, Heights, IL) diluted 1:1500 in Blotto for 1 hr at room
temperature, visualized using the ECL method (Amersham), exposed to
Kodak (Rochester, NY) x-ray film (5-15 min), and developed in a Kodak
automatic developer.
Antibodies. Antibody preparations included monoclonal
anti-GFAP (1:500; Sigma, St. Louis, MO), monoclonal anti-BrdU (1:400; Novocastra Laboratories), monoclonal anti-galactocerebroside (GC/O1) and monoclonals A2B5 and O4 (supernatants from mouse hybridomas O1, A2B5, and O4, 1:2; the gift of S. Pfeiffer, University of Connecticut), monoclonal GD3 (supernatant from mouse hybridoma, 1:2;
the gift of J. Goldman, Columbia University), affinity-purified rabbit
polyclonal antisera to ALK3, ALK6, and BMPRII (SMN) (each at 1:100; the
gifts of K. Miyazono, The Cancer Institute, Tokyo), and monoclonal
anti-BMP2 (1:1500; the gift of A. Celeste, Genetics Institute,
Cambridge, MA).
Growth factors. Recombinant human BMPs 2 and 4 were
provided by A. Celeste and J. Wozney, Genetics Institute. Recombinant human BMP7 (OP1) was provided by Marc Charette and Creative
Biomolecules, Cambridge, MA. BFGF and PDGF were obtained from
Collaborative Biomedical, Bedford, MA.
Quantification. Cell counts per well were calculated
by counting representative fields of view making up one quarter of the total culture well area and multiplying by 4. Each experimental value
represents the mean ± SEM of three replicate culture wells. Similar results were obtained in experiments from two additional cellular preparations performed in triplicate. Significance was determined by one-way ANOVA and the unpaired t test;
*p 0.05, **p 0.01, and
***p 0.001.
RESULTS
Bone morphogenetic proteins promote O-2A differentiation into
astrocytes and suppress oligodendroglial differentiation
Cultures of O-2As grown in SFM contained cells that began as
95% A2B5-immunoreactive and 75% O4-immunoreactive that over time
displayed increasing numbers of GC-immunoreactive oligodendrocytes (Figs. 1, 2B). The
number of GFAP-immunoreactive astrocytes declined over 7 d (Fig.
2A). As described previously (Raff et al., 1983 ), O-2As grown in FBS-supplemented medium developed into a near-uniform population of GFAP-immunoreactive astrocytes within 3 d, with very
few oligodendrocytes (data not shown). Treatment of O-2As with BMP2 (10 ng/ml) in SFM promoted the development of GFAP-immunoreactive astroglia
(Figs. 1, 2A), while suppressing O-2A development
into GC-immunoreactive oligodendroglia (Figs. 1, 2B).
BMP treatment also suppressed the development of cells expressing
myelin 2 ,3 -cyclic nucleotide 3 -phosphodiesterase (myelin CNPase) and
the oligodendrocyte-specific isoform of glutathione-S-transferase (data
not shown). This effect was accompanied by an increase in survival of
O-2As as determined by an increase in the number of total cells (total
cell counts after 4 d: control, 1199 ± 174; BMP2-treated,
2739 ± 241, n = 3, p < .01),
despite a decrease in proliferation (Fig. 3). In both conditions,
95% of cells were A2B5-immunoreactive; in the control condition,
80% were O4-immunoreactive cells, whereas in the BMP2 condition,
only 50-60% of the cells were O4-immunoreactive. Dual-label
immunofluorescent analysis demonstrated that a subset of
GFAP-immunoreactive cells also expressed weak O4-immunoreactivity after
4 d of BMP2 treatment; however O4-immunoreactivity is lost by
7 d (data not shown). These observations suggest that the BMP oligodendrocyte-suppressive effect was not the result of increased death of oligodendrocytes or their precursors but of differentiation of
O-2As into astrocytes.
Fig. 1.
Effect of BMP2 on O-2A differentiation.
Photomicrographs of O-2As grown for 4 d with no added growth
factor (A, C) or BMP2 (10 ng/ml)
(B, D) and labeled with anti-GFAP
(A, B) or GC/O1 (C, D). E, Photomicrograph of O-2A cells at
the start of experimental manipulation labeled with anti-GD3. Scale
bar, 65 µm.
[View Larger Version of this Image (116K GIF file)]
Fig. 2.
Development of O-2A progenitors in the absence or
presence of BMP2 (10 ng/ml). O-2As in SFM were analyzed for GFAP
(A) or GC/O1 (B) immunoreactivity at days
1-4 and 7.
[View Larger Version of this Image (18K GIF file)]
Fig. 3.
Effect of the BMPs on O-2A proliferation. O-2As
treated with no added growth factor or BMP2 (10 ng/ml) were analyzed
for BrdU incorporation by immunocytochemistry on 4 successive
days.
[View Larger Version of this Image (20K GIF file)]
BMPs promote O-2A progenitor cell exit from cell cycle
An increase in the number of a given cell type may occur by
enhanced survival, proliferation, and/or differentiation of a precursor
population. TGF signals are known to sanction each of these
developmental effects in vitro (Kinglsey, 1994), depending on the cell types studied. Epidermal growth factor-responsive mouse
embryonic cells co-treated with the BMPs are less active mitotically
than are parallel cells grown in EGF alone (D'Alessandro and Wang,
1994 ). On the other hand, primary embryonic cortical cells and
conditionally immortalized hippocampal progenitor cells cultured in
serum-free conditions, in which proliferation is very limited, respond
to BMP treatment with an early increase in proliferation that subsides
after 2 d (our unpublished observations). Unlike type 1 astrocytes, which are thought to divide several times after acquiring
their mature morphological and antigenic phenotype, type 2 astrocytes
are thought to terminally differentiate at the time they exit from cell
cycle (Lillien and Raff, 1990 ). To determine the effect of the BMPs on
O-2A proliferation, untreated and BMP-treated (BMP2, 10 ng/ml) O-2A
progenitor cells were analyzed for BrdU incorporation on four
successive days. During the first and fourth days, there was no
significant difference between control and BMP-treated groups; however,
during the second and third days, BMP2 treatment significantly
decreased the number of proliferating cells (Fig. 3). To
define further the phenotype of proliferating cells in these
cultures, dual-label immunofluorescent analysis was performed
on control and BMP2-treated cultures. After a 24 hr BrdU
pulse, all BrdU-immunoreactive cells were A2B5-immunoreactive, and
not galactocerebroside or GFAP-immunoreactive, in both the control and
BMP2-treated cultures (data not shown). Given that BMP treatment
decreases proliferation while simultaneously increasing the total
number of O-2As and GFAP-immunoreactive cells (see above) (Fig.
2A), these results demonstrate that BMPs enhance
survival and astrocytic differentiation of O-2As and not the
proliferation of committed astroblasts. Consistent with the effects of
FBS, BMP-generated astrocytes differentiate earlier than
oligodendrocytes, suggesting that O-2A lineage fate is determined by
the availability of signals rather than by the ability to respond to
these signals (Raff, 1989 ).
BMP effects on astrocyte induction are dose-dependent and are not
mimicked by other members of the TGF superfamily
TGF cytokines have been shown to have complex patterns of
expression in the CNS and to have different effects depending on the
specific ligand, concentration, and cell type studied (Flanders et al.,
1991 ; Poulsen et al., 1994 ). To investigate the specificity of the
effects demonstrated with BMP2 on O-2A progenitor cells, O-2A cultures
were treated with no added growth factor, with factors from two
distinct BMP subclasses, or with members of three other TGF
subclasses [TGF 1, activin, and glial-derived neurotrophic factor
(GDNF)]. After 4 d in culture, BMPs 2, 4, and 7 each displayed potent dose-dependent potentiation of the number and morphological differentiation of GFAP-immunoreactive astrocytes, with suppression of
the number of GC-immunoreactive oligodendrocytes (Fig.
4). BMPs 2 and 4 exhibited similar efficacy at 10
ng/ml, but differed at 1 ng/ml, in which BMP4 was more potent both in
astrocyte induction and oligodendrocyte suppression. BMP7 was somewhat
less efficacious in both astrocyte induction and oligodendrocyte
suppression. Preliminary studies with other BMP family members
demonstrate a similar range of effects (data not shown). In contrast to
the BMPs, TGF 1, activin, and GDNF, representatives of three distinct
TGF subclasses, failed to promote astroglial development (Fig.
5). These observations suggest that the
astroglial-inductive effects are specified by a discrete subset of
TGF superfamily cytokines known to share common receptor
subunits.
Fig. 4.
O-2A dose responses to BMPs 2, 4,
and 7. O-2As treated with no added growth factor or BMPs
2, 4, or 7 at 0.1, 1, 10, or 30 ng/ml
were grown for 4 d and analyzed for GFAP (A) and
GC/O1 (B) immunoreactivity.
[View Larger Version of this Image (31K GIF file)]
Fig. 5.
Comparison of BMP effects with other TGF
cytokines. O-2As were treated with TGF 1, activin, or GDNF (0.5 or 10 ng/ml) for 4 d, analyzed for GFAP and GC/O1 immunoreactivity, and
compared with control and BMP2 (10 ng/ml)-treated cultures.
[View Larger Version of this Image (24K GIF file)]
Responsiveness to the BMPs is temporally and
developmentally regulated
Developing SVZ progenitor cells are exposed to changing
microenvironments as they begin to migrate out of the SVZ. As a result, progenitor cells may be exposed to a given extracellular signal for
only a brief period of time. Furthermore, cells of the same lineage may
gain or lose responsiveness to a given extracellular signal as they
progress through different developmental stages. To examine whether
continuous exposure to the BMPs is required to maintain the astroglial
phenotype, O-2As were treated with BMP2 (10 ng/ml) for various temporal
intervals, and then placed in SFM without BMPs for the remainder of the
observation period. BMP treatment for one hr was sufficient to increase
the number of astrocytes 5-fold and decrease the number of
oligodendrocytes more than three-fold (Fig. 6A).
Astrocytes generated after brief BMP application displayed a mature
morphological and antigenic phenotype similar to cells continuously
treated with the BMPs. Increasing the BMP exposure time resulted in a
greater number of GFAP-immunoreactive astrocytes and fewer
GC-immunoreactive oligodendrocytes, with exposure for 96 hr resulting
in maximal trophic effects. Thus the predominant effect of the BMPs is
on the establishment of the astroglial phenotype rather than the maintenance of it.
Fig. 6.
The effects of altered timing of BMP treatment on
O-2A differentiation. A, Early withdrawal; cultures were
treated with BMP2 (10 ng/ml) at the start of the experiment for 1, 24, 48, or 96 hr, washed three times, and replaced in SFM for the remainder of the experimental period. Controls remained untreated or treated with
BMP2 (10 ng/ml) throughout the experimental period. After 7 d,
cultures were analyzed for GFAP and GC/O1 immunoreactivity. B, Late addition; cultures were treated with BMP2 (10 ng/ml) after variable delays of 24, 48, or 96 hr and were analyzed as
in A, using the same controls.
[View Larger Version of this Image (22K GIF file)]
Given that O-2As undergoing terminal differentiation exit from cell
cycle and are no longer susceptible to the astroglial-inductive effects
of FBS, we predicted that delaying O-2A BMP treatment would attenuate
the astrocyte-inductive and oligodendrocyte-suppressive effects. To
examine whether O-2A responsiveness to the BMPs changes during
development, O-2As were initially cultured in SFM without added growth
factors to allow progression through sequential oligodendroglial developmental stages and were then treated after variable time intervals (24, 48, and 96 hr) with BMP2 (10 ng/ml). Our results indicate that as O-2As differentiate in SFM toward postmitotic oligodendrocytes, their responsiveness to the BMPs is attenuated (Fig.
6B). Even with delayed addition at 96 hr, however,
BMP treatment increases significantly the number of GFAP-immunoreactive
cells and decreases the number of GC-immunoreactive cells that develop (compare Fig. 6B with
Fig.2A,B). These results suggest
that the BMPs operate maximally when the majority of cells are actively proliferating and that a brief early exposure to the BMPs has a lasting
effect on the establishment and maintenance of the differentiated astroglial phenotype.
BMP receptors are expressed by O-2As
Given the uniform response of O-2As to the BMPs, we predicted that
O-2A progenitor cells would express type I and type II BMP receptor
subunits. To examine the expression of BMP receptors, we analyzed O-2A
progenitors by dual-label immunofluorescence with antibodies that
recognize O-2As (A2B5 and O4) and affinity-purifed polyclonal
antibodies to BMP type I receptor subunits BMPRIa and BMPRIb and the
type II receptor subunit BMPRII. Virtually all cells immunoreactive to
the O-2A-specific antibody O4 expressed BMPRII (Fig.
7B) and BMPRIb (Fig. 7D); the
majority also expressed BMPRIa (Fig. 7F). Identical
results were seen with A2B5-immunoreactive cells (data not shown).
Furthermore, BMP receptor subunits were not expressed by any nonO-2A
contaminating cells that were present (e.g., A2B5-negative or
O-4-negative cells). Expression of the transcripts for these receptor
subunits was also demonstrated by RT-PCR (data not shown). Thus, the
BMP receptor subunits that are necessary for BMP-directed signal
transduction are expressed by O-2As, suggesting that BMP astrocyte
induction represents a direct cellular effect on this progenitor
population.
Fig. 7.
O-2A expression of BMP type I and type II receptor
subunits. Photomicrographs of immunofluorescent dual-labeled O-2As with the lineage-specific antibody O4 (A,
C, E) and antisera to BMPRII (B), BMPRIb (D), and BMPRIa
(F). Each pair (A,
B; C, D; E,
F) represents the same field of view. Scale bar,
65 µm.
[View Larger Version of this Image (84K GIF file)]
BMP expression in vivo is
developmentally regulated
For the BMPs to play a role in glial development in
vivo, both ligand and receptor subunits must be expressed at the
appropriate time to mediate the proposed developmental effects. To
determine whether the expression of the BMPs is developmentally
regulated, we examined BMP2 expression in P8 and adult brain by Western
blot. Expression of BMP2 is significantly higher during the period of gliogenesis than it is in the adult (Fig. 8). Thus, BMP
ligand is expressed in the brain at a time when bipotent glial
progenitor cells are beginning to differentiate and may be susceptible
to the lineage-inductive effects of the BMPs demonstrated in
vitro.
Fig. 8.
Expression of BMP2 in P8 and adult brain. Western
blots were performed with a monoclonal antibody specific for BMP2. Indicates the 116 kDa (unprocessed) form of BMP2.
[View Larger Version of this Image (30K GIF file)]
DISCUSSION
Identification of a class of cytokines that promote astroglial
lineage commitment
Epigenetic signals that influence CNS lineage commitment
remain largely undefined. Previous work has identified several signals that modulate the proliferation and survival of O-2A progenitor cells
and that promote oligodendroglial differentiation of these bipotent
glial progenitors. The development of O-2As into astrocytes, however,
has required undefined inductive signals in FBS or meningeal ECM plus
CNTF. We now report that the BMPs, a subclass of the TGF
superfamily, promote astroglial differentiation and suppress oligodendroglial differentiation of oligodendroglial-astroglial progenitor cells. These dose-dependent effects are BMP
subclass-specific and implicate specific signal transduction pathways
mediated by BMP ligand-receptor subunit interactions.
The genesis of astrocytes has been the topic of much debate over the
past 15 years. Two models of gliogenesis were initially proposed, one
based largely on in vitro studies of optic nerve, and the
other on [3H]thymidine and retroviral labeling studies
in vivo. In the first model, astrocytes were proposed to
develop during two periods, an embryonic period, during which
protoplasmic astrocytes arise from the conversion of radial glia, and a
postnatal period, during which bipotent oligodendroglial-astroglial
progenitors are induced to differentiate into stellate astrocytes by
environmental cues. O-2A progenitors were proposed to be the in
vitro equivalent of the bipotent glial progenitor cell in
vivo. This model has been questioned because of the failure to
identify cells in vivo that co-express A2B5 and GFAP
immunoreactivity and the initial failure to detect a progenitor, the
in vivo progeny of which includes both astrocytes and
oligodendrocytes (see Goldman et al., 1986 ; Curtis et al., 1988 ;
Lillien and Raff, 1990 ; Cameron and Rakic, 1991 ; Skoff and Knapp,
1991 ). The second model proposed that progenitor cells within the
embryonic VZ and SVZ are already committed to a specific fate. Although
a consensus has not yet been reached, several recent observations
suggest a model of gliogenesis that integrates aspects of both earlier
models. First, the recent identification of neonatal SVZ progenitors
that give rise to both oligodendrocytes and astrocytes (Levison and
Goldman, 1993 ) has renewed interest in signals that may influence
postnatal bipotent glial progenitor fate. A role for such regulated
environmental cues is suggested by the interesting observation that the
destination and timing of SVZ progenitor migration appear to correlate
with the ultimate phenotype of the progenitor's progeny. Cells that
migrate into gray matter tend to differentiate into astrocytes, and
cells that migrate into white matter tend to differentiate into
oligodendrocytes. Second, astrocytes derived from O-2A progenitors lose
A2B5 immunoreactivity over time in culture (Lillien and Raff, 1990 ; our
unpublished observation), suggesting that A2B5 immunoreactivity may
reflect the influence of the isolation and culture procedures, but may not be an appropriate criterion for classifying astrocytes into two
types. Thus, A2B5 immunoreactivity may not identify the astrocytic progeny of a bipotent glial progenitor in vivo. The
identification of multipotent and bipotent neural progenitors that
persist into adulthood (Norton et al., 1988 ; Gard and Pfeiffer, 1989 ;
Wolswijk and Noble, 1989; Reynolds and Weiss, 1992 ; Schwartz and
Wilson, 1992; Lois and Alvarez-Buylla, 1993 ) suggests that
environmental signals may continue to influence the fate of uncommitted
progenitor cells throughout postnatal life.
Our finding that the BMPs induce astroglial differentiation and
suppress oligodendroglial development of oligodendroglial-astroglial progenitors in vitro demonstrates that the BMPs may regulate
postnatal astrocytic lineage commitment of glial-restricted bipotent
progenitor cells. The BMP ligands and receptor subunits are expressed
in the developing CNS at the appropriate time to play such a role in vivo. We have also confirmed that O-2As express BMP
receptors in vitro. Other studies have suggested that the
BMPs may also promote astrocytic lineage commitment and/or
differentiation at an earlier embryonic developmental stage in cells
that express very low or no A2B5 immunoreactivity (D'Alessandro et
al., 1994 ; Gross et al., 1996 ). Additional support that the BMPs may
regulate neural lineage commitment comes from the recent report that
the BMPs specify the neuronal fate in multipotent neural crest
progenitor cells (Shah et al., 1996 ).
Previous investigations of O-2A differentiation have used undefined
factors in FBS, or meningeal ECM plus CNTF, to induce the astroglial
phenotype. Our results with the BMPs mimic FBS-induced astroglial
differentiation both temporally and developmentally and contrast with
the effects of CNTF with or without meningeal ECM. The BMP effect on
O-2A morphology and antigenic phenotype, like FBS, is apparent at
48-72 hr and persists. CNTF causes transient expression of GFAP in a
minority of cells at 24 hr, with loss of GFAP-immunoreactivity and
development into oligodendrocytes by 72 hr (Hughes et al., 1988 ). Thus,
CNTF alone does not influence O-2A lineage fate. When combined with
unidentified molecules in meningeal or endothelial ECM, CNTF results in
the stable induction of the astroglial phenotype (Lillien et al.,
1990 ). The BMPs, like FBS, appear to induce astrocytes at both pre-O4
and O4-immunoreactive developmental stages, whereas meningeal ECM plus
CNTF or LIF only induces astrocytes at the pre-O4 stage (Gard et al.,
1995 ). Because serum contains endogenous BMP ligand (Perides et al.,
1994 ), the BMPs may largely mediate the astrocyte-inductive effects of
serum. The astrocytes that develop in the presence of the BMPs are
similar phenotypically to those grown in FBS, including a subpopulation that co-expresses O4/GFAP immunoreactivity. BMP-generated astrocytes differ, however, in that they appear to lose A2B5 immunoreactivity more
rapidly than those grown in FBS (data not shown). If the BMPs are, in
fact, an inductive signal for astrocytic lineage commitment in
vivo, this may explain partially the difficulty in detecting
A2B5/GFAP dual-immunoreactive cells in vivo.
Temporal/developmental window of BMP effects
Brief exposure to the BMPs is sufficient to initiate an astroglial
lineage program that is sustained without additional dependence on the
presence of exogenous BMPs. Extended treatment intervals cause an
increase in the number of cells induced to the astroglial phenotype.
Such trophic actions imply the presence of an astrocyte differentiation
switch that can be constitutively activated with a brief stimulus. Work
in the PNS has suggested such a role for glial growth factor, a ligand
of the neuregulin family (Shah et al., 1994 ). The concept that the BMPs
play a role in neural lineage commitment is supported by the recent
report that the BMPs specify the neuronal fate in multipotent neural
crest progenitor cultures (Anderson, 1996). The identification of the
nuclear protein encoded by the gene glial cells missing in
Drosophila that acts as a binary switch controlling neuronal
versus glial fate presents a potential downstream mechanism for such
lineage-inductive effects (Hosoya et al., 1995 ; Jones et al., 1995 ).
The BMP signal transduction pathway may stimulate expression of such a
switch that once activated, positively regulates astroglial lineage
commitment. Survival of committed astrocytes may occur by autocrine
signaling mechanisms using BMP or other signals or may occur
autonomously.
Experiments with delayed BMP treatment suggest a gradual but
progressive loss of O-2A bipotency and BMP responsiveness that coincides with cell cycle exit and oligodendroglial terminal
differentiation. The mechanisms that mediate the cellular transitions
from proliferative, bipotent, and BMP responsive to postmitotic,
unipotent, and BMP unresponsive are unknown. TGF cytokines are
thought to inhibit proliferation through regulation of cyclin-dependent
kinase inhibitors (Hannon and Beach, 1994 ). The relationship between
cell cycle regulatory proteins and lineage restriction in neural cells
has not been investigated. By demonstrating accelerated cell cycle exit
with astroglial differentiation, our results suggest that the BMPs
co-regulate proliferative capacity and lineage induction.
How these findings relate to in vivo development remains to
be determined. Establishment of an astrocyte-inductive role for the
BMPs in normal neural development is plausible given the in vivo expression of BMP ligands and receptor subunits and the
identification of potentially responsive bipotent progenitor cells
in vivo. This hypothesis will require validation in an
in vivo model in which BMP signal transduction can be both
positively and negatively manipulated without resulting in early
lethality. With the increasing appreciation of immature cells present
in the adult SVZ and subcortical white matter (Gensert and Goldman,
1996 ), a possible role for the BMPs also exists within several
pathological contexts. TGF cytokine expression is regulated in CNS
injury (Logan et al., 1992 ). If this applies to the BMPs as well, this
major TGF subclass may regulate the expanded repertoire of
astroglial phenotypes generated in the pathologically altered CNS
environment.
FOOTNOTES
Received Sept. 4, 1996; revised Feb. 3, 1997; accepted March 24, 1997.
This work was supported by the Muscular Dystrophy Association and an
Irma T. Hirschl Career Scientist Award (M.F.M), and grants from
National Institutes of Health (J.A.K.). We thank Steve Pfeiffer and Jim
Goldman for providing us with antibody hybridoma cell lines. We thank
Anthony Celeste, John Wozney, and Genetics Institute for providing us
with BMPs 2 and 4 and the monoclonal antibody to BMP2; and Marc
Charette and Creative Biomolecules for providing us with OP1 (BMP7). We
thank K. Miyazono for antisera to ALK3, ALK6, and BMPRII. We thank Rick
Cohen for technical assistance.
Correspondence should be addressed to Dr. Peter C. Mabie, Department of
Neurology, Albert Einstein College of Medicine, Kennedy Center, Room
401, 1300 Morris Park Avenue, Bronx, NY 10461.
REFERENCES
-
Anderson DJ
(1989)
The neural crest cell lineage problem: neuropoiesis?
Neuron
3:1-12[Web of Science][Medline].
-
Barres BA,
Raff MC
(1994)
Control of oligodendrocyte number in the developing rat optic nerve.
Neuron
12:935-942[Web of Science][Medline].
-
Cameron RS,
Rakic P
(1991)
Glial cell lineage in the cerebral cortex: a review and synthesis.
Glia
4:124-137[Web of Science][Medline].
-
Curtis R,
Cohen J,
Fok-Seang J,
Hanley MR,
Gregson NA,
Reynolds R,
Wilkin GP
(1988)
Development of macroglial cells in rat cerebellum. I. Use of antibodies to follow early in vivo development and migration of oligodendrocytes.
J Neurocytol
17:43-54[Web of Science][Medline].
-
D'Alessandro JS,
Wang EA
(1994)
Bone morphogenetic proteins inhibit proliferation, induce reversible differentiation and prevent cell death in astrocyte lineage cells.
Growth factors
11:45-52[Web of Science][Medline].
-
D'Alessandro JS,
Yetz-Aldape J,
Wang EA
(1994)
Bone morphogenetic proteins induce differentiation in astrocyte lineage cells.
Growth Factors
11:53-69[Web of Science][Medline].
-
Dudley AT,
Lyons KM,
Robertson EJ
(1995)
A requirement for bone morphogenetic protein-7 during development of the mammalian kidney and eye.
Genes Dev
9:2795-2807[Abstract/Free Full Text].
-
Flanders KC,
Ludecke G,
Engels S,
Cissel DS,
Roberts AB,
Kondaiah P,
Lafyatis R,
Sporn MB,
Unsicker K
(1991)
Localization and actions of transforming growth factor-betas in the embryonic nervous system.
Development
113:183-191[Abstract].
-
Franklin RJ,
Blakemore WF
(1995)
Glial-cell transplantation and plasticity in the O-2A lineage implications for CNS repair.
Trends Neurosci
18:151-156[Web of Science][Medline].
-
Gard AL,
Pfeiffer SE
(1989)
Oligodendrocyte progenitors isolated directly from developing telencephalon at a specific phenotypic stage: myelinogenic potential in a defined environment.
Development
106:119-132[Abstract].
-
Gard AL,
Williams WC,
Burrell MR
(1995)
Oligodendroblasts distinguished from O-2A glial progenitors by surface phenotype (O4+GalC
) and response to cytokines using signal transducer LIFR .
Dev Biol
167:596-608[Web of Science][Medline]. -
Gensert JM,
Goldman JE
(1996)
In vivo characterization of endogenous proliferating cells in adult rat subcortical white matter.
Glia
17:39-51[Web of Science][Medline].
-
Godfraind C,
Friedrich VL,
Holmes KV,
Dubois-Dalq M
(1989)
In vivo analysis of glial cell phenotypes during a viral demyelinating disease in mice.
J Cell Biol
109:2405-2416[Abstract/Free Full Text].
-
Goldman JE,
Geier S,
Hirano M
(1986)
Differentiation of astrocytes and oligodendrocytes from germinal matrix cells in primary culture.
J Neurosci
6:52-60[Abstract].
-
Graham A,
Francis-West P,
Brickell P,
Lumsden A
(1994)
The signalling molecule BMP4 mediates apoptosis in the rhombencephalic neural crest.
Nature
372:684-686[Medline].
-
Gross RE,
Mehler MF,
Mabie PC,
Zang Z,
Santschi L,
Kessler JA
(1996)
Bone morphogenetic proteins promote astroglial lineage commitment by mammalian subventricular zone progenitor cells.
Neuron
17:595-606[Web of Science][Medline].
-
Hannon GJ,
Beach D
(1994)
p15INK4B is a potential effector of TGF
-induced cell cycle arrest.
Nature
371:257-260[Medline]. -
Harland RM
(1994)
The transforming growth factor beta family and induction of the vertebrate mesoderm: bone morphogenetic proteins are ventral inducers.
Proc Natl Acad Sci USA
91:10243-10246[Free Full Text].
-
Hogan BL
(1996)
Bone morphogenetic proteins: multifunctional regulators of vertebrate development.
Genes Dev
10:1580-1594[Free Full Text].
-
Hosoya T,
Takizawa K,
Nitta K,
Hotta Y
(1995)
Glial cells missing: a binary switch between neuronal and glial determination in Drosophila.
Cell
82:1025-1036[Web of Science][Medline].
-
Hughes S,
Lillien LE,
Raff MC,
Rohrer H,
Sendtner M
(1988)
Ciliary neurotrophic factor induces type 2 astrocyte differentiation in culture.
Nature
335:70-73[Medline].
-
Jan YN,
Jan LY
(1995)
Maggot's hair and bug's eye: role of cell interactions and intrinsic factors in cell fate specification.
Neuron
14:1-5[Web of Science][Medline].
-
Jones BW,
Fetter RD,
Tear G,
Goodman CS
(1995)
Glial cells missing: a genetic switch that controls glial versus neuronal fate.
Cell
82:1013-1023[Web of Science][Medline].
-
Jones CM,
Lyons KM,
Hogan BL
(1991)
Involvement of bone morphogenetic protein-4 and Vgr-a in morphogenesis and neurogenesis in the mouse.
Development
111:531-542[Abstract].
-
Kingsley DM
(1994)
The TGF
superfamily: new members, new receptors, and new genetic tests of function in different organisms.
Genes Dev
8:133-146[Free Full Text]. -
Letsou A,
Arora K,
Wrana JL,
Simin K,
Twombly V,
Jamal J,
Staehling-Hampton K,
Hoffmann FM,
Gelbart WM,
Massague J,
O'Connor MB
(1995)
Drosophila dpp signaling is mediated by the punt gene product: a dual ligand-binding type II receptor of the TGF
receptor family.
Cell
80:899-908[Web of Science][Medline]. -
Levison SW,
Goldman JE
(1993)
Both oligodendrocytes and astrocytes develop from progenitors in the subventricular zone of postnatal rat forebrain.
Neuron
10:201-212[Web of Science][Medline].
-
Liem KF,
Tremmi G,
Roelink H,
Jessell TM
(1995)
Dorsal differentiation of neural plate cells induced by BMP-mediated signals from epidermal ectoderm.
Cell
82:969-979[Web of Science][Medline].
-
Lillien LE,
Raff M
(1990)
Differentiation signals in the CNS: type 2 astrocyte development in vitro as a model system.
Neuron
5:110-119.
-
Lillien LE,
Sendtner M,
Raff MC
(1990)
Extracellular matric-associated molecules collaborate with ciliary neurotrophic factor to induce type-2 astrocyte development.
J Cell Biol
111:635-644[Abstract/Free Full Text].
-
Logan A,
Frautschy SA,
Gonzalez AM,
Sporn M,
Baird A
(1992)
Evidence of endogenous regulatory function of transforming growth factor-beta 1 in experimental allergic encephalomyelitis.
Brain Res
587:216-225[Web of Science][Medline].
-
Lois C,
Alvarez-Buylla A
(1993)
Proliferating subventricular zone cells in the adult mammalian forebrain can differentiate into neurons and glia.
Proc Natl Acad Sci USA
90:2074-2077[Abstract/Free Full Text].
-
Lubetzki C,
Goujet-Zalc C,
Demerens C,
Danos O,
Zalc B
(1992)
Clonal segregation of oligodendrocytes and astrocytes during in vitro differentiation of glial progenitor cells.
Glia
6:289-300[Web of Science][Medline].
-
Luo G,
Hofmann C,
Bronckers AL,
Sohocki M,
Bradley A,
Karsenty G
(1995)
Bmp-7 is an inducer of nephrogenesis, and is also required for eye development and skeletal patterning.
Genes Dev
9:2808-2820[Abstract/Free Full Text].
-
Luskin MB,
Pearlman A,
Sanes JR
(1988)
Cell lineage in the cerebral cortex of mouse studied in vivo and in vitro with a recombinant retrovirus.
Neuron
1:635-647[Web of Science][Medline].
-
McCarthy KD,
DeVellis J
(1980)
Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue.
J Cell Biol
85:890-902[Abstract/Free Full Text].
-
Mishina Y,
Susuki A,
Ueno N,
Behringer RR
(1995)
BMPr encodes a type I bone morphogenetic protein receptor that is essential for gastrulation during mouse embryogenesis.
Genes Dev
9:3027-3037[Abstract/Free Full Text].
-
Norton WT,
Farooq M,
Chiu FC,
Bottenstein JE
(1988)
Pure astrocyte cultures derived from cells isolated from mature brain.
Glia
1:403-414[Web of Science][Medline].
-
Perides G,
Safran RM,
Downing LA,
Charness ME
(1994)
Regulation of neural cell adhesion molecule and L1 by the transforming growth factor-beta superfamily. Selective effects of the bone morphogenetic proteins.
J Biol Chem
269:765-770[Abstract/Free Full Text].
-
Poulsen KT,
Armanini MP,
Klein RD,
Hynes MA,
Phillips HS,
Rosenthal A
(1994)
TGF beta 2 and TGF beta 3 are potent survival factors for midbrain dopaminergic neurons.
Neuron
13:1245-1252[Web of Science][Medline].
-
Price J,
Thurlow L
(1988)
Cell lineage in the rat cerebral cortex: a study using retroviral-mediated gene transfer.
Development
104:473-482[Abstract/Free Full Text].
-
Raff MC
(1989)
Glial cell diversification in the rat optic nerve.
Science
243:1450-1455[Abstract/Free Full Text].
-
Raff MC,
Miller RH,
Noble M
(1983)
A glial progenitor cell that develops in vitro into an astrocyte or oligodendrocyte depending on culture medium.
Nature
303:390-396[Medline].
-
Reissmann E,
Ernsberger U,
Francis-West PH,
Rugeger D,
Brickell PM,
Rohrer H
(1996)
Involvement of bone morphogenetic protein-4 and bone morphogenetic protein-7 in the differentiation of the adrenergic phenotype in developing sympathetic neurons.
Development
122:2079-2088[Abstract].
-
Reynolds BA,
Weiss S
(1992)
Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system.
Science
255:1707-1710[Abstract/Free Full Text].
-
Rosenzweig BL,
Imamura T,
Okadome T,
Cox GN,
Yamashita H,
ten Dijke P,
Heldin CH,
Miyazono K
(1995)
Cloning and characterization of a human type II receptor for bone morphogenetic proteins.
Proc Natl Acad Sci USA
92:7632-7636[Abstract/Free Full Text].
-
Ruberte E,
Marty T,
Nellen D,
Affolter M,
Basler K
(1995)
An absolute requirement for both the type II and type I receptors, punt and thick veins, for dpp signaling in vivo.
Cell
80:889-897[Web of Science][Medline].
-
Sasai Y,
Lu B,
Steinbeisser H,
DeRobertis EM
(1995)
Regulation of neural induction by the Chd and Bmp-4 antagonistic patterning signals in Xenopus.
Nature
376:333-336[Medline].
-
Schluesener HJ,
Meyermann R
(1994)
Expression of BMP-6, a TGFb-related morphogenetic cytokine, in rat radial glial cells.
Glia
12:161-164[Web of Science][Medline].
-
Shah NM,
Marchionni MA,
Isaacs I,
Stroobant P,
Anderson DJ
(1994)
Glial growth factor restricts mammalian neural crest stem cells to a glial fate.
Cell
77:349-360[Web of Science][Medline].
-
Shah NM,
Groves AK,
Anderson DJ
(1996)
Alternative neural crest cell fates are instructively promoted by TGF
superfamily members.
Cell
85:331-343[Web of Science][Medline]. -
Skoff RP,
Knapp PE
(1991)
Division of astroblasts and oligodendroblasts in postnatal rodent brain: evidence for separate astrocyte and oligodendrocyte lineages.
Glia
4:165-174[Web of Science][Medline].
-
Temple S,
Raff MC
(1985)
Differentiation of a bipotential glial progenitor cell in single cell microculture.
Nature
313:223-225[Medline].
-
ten Dijke P,
Franzen P,
Yamashita H,
Ichijo H,
Heldin CH,
Miyazono K
(1994a)
Serine/threonine kinase receptors.
Prog Growth Factor Res
5:55-72[Medline].
-
ten Dijke P,
Ichijo H,
Franzen P,
Schulz P,
Saras J,
Toyoshima H,
Heldin CH,
Miyazono K
(1994b)
Activin receptor-like kinases: a novel subclass of cell-surface receptors for BMP-2 and BMP-4 from NIH 3T3 cells.
Mol Cell Biol
14:5961-5974[Abstract/Free Full Text].
-
ten Dijke P,
Yamashita H,
Sampath TK,
Reddi AH,
Estevez M,
Riddle DL,
Ichijo H,
Heldin CH,
Miyazono K
(1994c)
Identification of type I receptors for osteogenic protein-1 and bone morphogenetic protein-4.
J Biol Chem
269:16985-16988[Abstract/Free Full Text].
-
Wilson PA,
Hemmati-Brivanlou A
(1995)
Induction of epidermis and inhibition of neural fate by Bmp-4.
Nature
376:331-333[Medline].
-
Winnier G,
Blessing M,
Labosky PA,
Hogan BL
(1995)
Bone morphogenetic protein-4 is required for mesoderm formation and patterning in the mouse.
Genes Dev
9:2105-2116[Abstract/Free Full Text].
-
Wolswijk G,
Noble M
(1992)
Cooperation between PDGF and FGF converts slowly dividing O-2A adult progenitor cells to rapidly dividing cells with characteristics of O-2A perinatal progenitor cells.
J Cell Biol
118:889-900[Abstract/Free Full Text].
This article has been cited by other articles:

|
 |

|
 |
 
B. Neumeister, A. Grabosch, O. Basak, R. Kemler, and V. Taylor
Neural Progenitors of the Postnatal and Adult Mouse Forebrain Retain the Ability to Self-Replicate, Form Neurospheres, and Undergo Multipotent Differentiation In Vivo
Stem Cells,
March 1, 2009;
27(3):
714 - 723.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. H. Reyes, K. S. O'Shea, N. L. Wys, J. M. Velkey, D. M. Prieskorn, K. Wesolowski, J. M. Miller, and R. A. Altschuler
Glutamatergic Neuronal Differentiation of Mouse Embryonic Stem Cells after Transient Expression of Neurogenin 1 and Treatment with BDNF and GDNF: In Vitro and In Vivo Studies
J. Neurosci.,
November 26, 2008;
28(48):
12622 - 12631.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Jiao and D. F. Chen
Induction of Neurogenesis in Nonconventional Neurogenic Regions of the Adult Central Nervous System by Niche Astrocyte-Produced Signals
Stem Cells,
May 1, 2008;
26(5):
1221 - 1230.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. D Allen
Temporal and epigenetic regulation of neurodevelopmental plasticity
Phil Trans R Soc B,
January 12, 2008;
363(1489):
23 - 38.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X. Cheng, Y. Wang, Q. He, M. Qiu, S. R. Whittemore, and Q. Cao
Bone Morphogenetic Protein Signaling and Olig1/2 Interact to Regulate the Differentiation and Maturation of Adult Oligodendrocyte Precursor Cells
Stem Cells,
December 1, 2007;
25(12):
3204 - 3214.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. Coskun, J. Zhao, and Y. E. Sun
Neurons or Glia? Can SHP2 Know It All?
Sci. Signal.,
October 30, 2007;
2007(410):
pe58 - pe58.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. A. Lyssiotis, J. Walker, C. Wu, T. Kondo, P. G. Schultz, and X. Wu
Inhibition of histone deacetylase activity induces developmental plasticity in oligodendrocyte precursor cells
PNAS,
September 18, 2007;
104(38):
14982 - 14987.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Samanta, G. M. Burke, T. McGuire, A. J. Pisarek, A. Mukhopadhyay, Y. Mishina, and J. A. Kessler
BMPR1a Signaling Determines Numbers of Oligodendrocytes and Calbindin-Expressing Interneurons in the Cortex
J. Neurosci.,
July 11, 2007;
27(28):
7397 - 7407.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Gossrau, J. Thiele, R. Konang, T. Schmandt, and O. Brustle
Bone Morphogenetic Protein-Mediated Modulation of Lineage Diversification During Neural Differentiation of Embryonic Stem Cells
Stem Cells,
April 1, 2007;
25(4):
939 - 949.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. C. Dugas, Y. C. Tai, T. P. Speed, J. Ngai, and B. A. Barres
Functional Genomic Analysis of Oligodendrocyte Differentiation
J. Neurosci.,
October 25, 2006;
26(43):
10967 - 10983.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Deleyrolle, S. Marchal-Victorion, C. Dromard, V. Fritz, M. Saunier, J.-C. Sabourin, C. Tran Van Ba, A. Privat, and J.-P. Hugnot
Exogenous and Fibroblast Growth Factor 2/Epidermal Growth Factor-Regulated Endogenous Cytokines Regulate Neural Precursor Cell Growth and Differentiation
Stem Cells,
March 1, 2006;
24(3):
748 - 762.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. E. Kendall, C. Battelli, S. Irwin, J. G. Mitchell, C. A. Glackin, and J. M. Verdi
NRAGE Mediates p38 Activation and Neural Progenitor Apoptosis via the Bone Morphogenetic Protein Signaling Cascade
Mol. Cell. Biol.,
September 1, 2005;
25(17):
7711 - 7724.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Chojnacki and S. Weiss
Isolation of a Novel Platelet-Derived Growth Factor-Responsive Precursor from the Embryonic Ventral Forebrain
J. Neurosci.,
December 1, 2004;
24(48):
10888 - 10899.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Kondo and M. Raff
Chromatin remodeling and histone modification in the conversion of oligodendrocyte precursors to neural stem cells
Genes & Dev.,
December 1, 2004;
18(23):
2963 - 2972.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Samanta and J. A. Kessler
Interactions between ID and OLIG proteins mediate the inhibitory effects of BMP4 on oligodendroglial differentiation
Development,
September 1, 2004;
131(17):
4131 - 4142.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Brederlau, R. Faigle, M. Elmi, A. Zarebski, S. Sjoberg, M. Fujii, K. Miyazono, and K. Funa
The Bone Morphogenetic Protein Type Ib Receptor Is a Major Mediator of Glial Differentiation and Cell Survival in Adult Hippocampal Progenitor Cell Culture
Mol. Biol. Cell,
August 1, 2004;
15(8):
3863 - 3875.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Takanaga, T. Yoshitake, S. Hara, C. Yamasaki, and M. Kunimoto
cAMP-induced Astrocytic Differentiation of C6 Glioma Cells Is Mediated by Autocrine Interleukin-6
J. Biol. Chem.,
April 9, 2004;
279(15):
15441 - 15447.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Okano-Uchida, T. Himi, Y. Komiya, and Y. Ishizaki
Cerebellar granule cell precursors can differentiate into astroglial cells
PNAS,
February 3, 2004;
101(5):
1211 - 1216.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Faigle, A. Brederlau, M. Elmi, Y. Arvidsson, T. S. Hamazaki, H. Uramoto, and K. Funa
ASK1 Inhibits Astroglial Development via p38 Mitogen-Activated Protein Kinase and Promotes Neuronal Differentiation in Adult Hippocampus-Derived Progenitor Cells
Mol. Cell. Biol.,
January 1, 2004;
24(1):
280 - 293.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Imitola, E. Y. Snyder, and S. J. Khoury
Genetic programs and responses of neural stem/progenitor cells during demyelination: potential insights into repair mechanisms in multiple sclerosis
Physiol Genomics,
August 15, 2003;
14(3):
171 - 197.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Mekki-Dauriac, E. Agius, P. Kan, and P. Cochard
Bone morphogenetic proteins negatively control oligodendrocyte precursor specification in the chick spinal cord
Development,
March 13, 2003;
129(22):
5117 - 5130.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Y. S. Oh, A. Denninger, J. S. Colvin, A. Vyas, S. Tole, D. M. Ornitz, and R. Bansal
Fibroblast Growth Factor Receptor 3 Signaling Regulates the Onset of Oligodendrocyte Terminal Differentiation
J. Neurosci.,
February 1, 2003;
23(3):
883 - 894.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Gregori, C. Proschel, M. Noble, and M. Mayer-Proschel
The Tripotential Glial-Restricted Precursor (GRP) Cell and Glial Development in the Spinal Cord: Generation of Bipotential Oligodendrocyte-Type-2 Astrocyte Progenitor Cells and Dorsal-Ventral Differences in GRP Cell Function
J. Neurosci.,
January 1, 2002;
22(1):
248 - 256.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Kondo and M. Raff
Oligodendrocyte Precursor Cells Reprogrammed to Become Multipotential CNS Stem Cells
Science,
September 8, 2000;
289(5485):
1754 - 1757.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
S. E. Stringer, M. Mayer-Proschel, A. Kalyani, M. Rao, and J. T. Gallagher
Heparin Is a Unique Marker of Progenitors in the Glial Cell Lineage
J. Biol. Chem.,
September 3, 1999;
274(36):
25455 - 25460.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. C. Mabie, M. F. Mehler, and J. A. Kessler
Multiple Roles of Bone Morphogenetic Protein Signaling in the Regulation of Cortical Cell Number and Phenotype
J. Neurosci.,
August 15, 1999;
19(16):
7077 - 7088.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. DOCAGNE, O. NICOLE, H. H. MARTI, E. T. MacKENZIE, A. BUISSON, and D. VIVIEN
Transforming growth factor-{beta}1 as a regulator of the serpins/t-PA axis in cerebral ischemia
FASEB J,
August 1, 1999;
13(11):
1315 - 1324.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
M. F. Mehler and J. A. Kessler
Progenitor Cell Biology: Implications for Neural Regeneration
Arch Neurol,
July 1, 1999;
56(7):
780 - 784.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S.-Z. Lin, B. J. Hoffer, P. Kaplan, Y. Wang, and C. Y. Hsu
Osteogenic Protein-1 Protects Against Cerebral Infarction Induced by MCA Ligation in Adult Rats • Editorial Comment
Stroke,
January 1, 1999;
30(1):
126 - 133.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Marmur, J. A. Kessler, G. Zhu, S. Gokhan, and M. F. Mehler
Differentiation of Oligodendroglial Progenitors Derived from Cortical Multipotent Cells Requires Extrinsic Signals Including Activation of gp130/LIFbeta Receptors
J. Neurosci.,
December 1, 1998;
18(23):
9800 - 9811.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. J. Kalyani, D. Piper, T. Mujtaba, M. T. Lucero, and M. S. Rao
Spinal Cord Neuronal Precursors Generate Multiple Neuronal Phenotypes in Culture
J. Neurosci.,
October 1, 1998;
18(19):
7856 - 7868.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. G. Hanson Jr, S. Shen, A. P. Wiemelt, F. A. McMorris, and B. A. Barres
Cyclic AMP Elevation Is Sufficient to Promote the Survival of Spinal Motor Neurons In Vitro
J. Neurosci.,
September 15, 1998;
18(18):
7361 - 7371.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Smith, E. Ladi, M. Mayer-Proschel, and M. Noble
Redox state is a central modulator of the balance between self-renewal and differentiation in a dividing glial precursor cell
PNAS,
August 29, 2000;
97(18):
10032 - 10037.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|